Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.
Title | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Pyrgidis, N., Vakalopoulos I., & Sountoulides P. |
Journal | Hormones (Athens) |
Date Published | 2020 Nov 02 |
ISSN | 2520-8721 |
Abstract | PURPOSE: Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. We aimed to assess the endocrine and metabolic adverse events associated with treatment using ARAT compounds. |
DOI | 10.1007/s42000-020-00251-5 |
Alternate Journal | Hormones (Athens) |
PubMed ID | 33140306 |